Table 1.

Part A. Associations between genetic variation in SST and the SSTR genes and prostate cancer risk and circulating hormone levels

Gene marker order-common/rare alleleHaplotypeFrequency (controls)Prostate cancer risk
IGFI
IGFBP3
OR (95% CI)*P*β-estimate (95% CI)Pβ-estimate (95% CI)P
SSTGTTT(2 copies)25.4%1.0 (Reference)0 (Reference)0 (Reference)
rs10513817-G/TGTTT(1 copy)50.5%1.1 (0.9 -1.2)0.4910 (−1 to 21)0.0996 (−35 to 226)0.15
rs9824174-T/CGTCT(1 copy)24.7%1.1 (0.9 -1.2)0.453 (−10 to 16)0.6359 (−96 to 213)0.46
rs16862418-T/CGTCT(2 copies)2.4%1.1 (0.7 -1.7)0.6913 (−20 to 46)0.45361 (−25 to 746)0.07
rs2378339-T/CGTTC(1 copy)22.3%1.0 (0.8 -1.1)0.52−4 (−17 to 9)0.51−26 (−178 to 127)0.74
GTTC(2 copies)1.7%0.9 (0.6 -1.5)0.771 (−36 to 38)0.9450 (−383 to 483)0.82
GCTC(1 copy)19.3%1.1 (0.9 -1.3)0.4717 (37709)0.0286 (−76 to 247)0.30
GCTC(2 copies)0.8%0.7 (0.4 -1.3)0.22−5 (−47 to 36)0.8134 (−452 to 519)0.89
TTTC(1 copy)19.5%1.3 (1.1 -1.5)0.01−3 (−17 to 12)0.702 (−166 to 169)0.98
TTTC(2 copies)1.1%0.7 (0.4 -1.2)0.2181 (23-138)0.006174 (−497 to 846)0.61
SSTR1CCC(2 copies)32.5%1.0 (Reference)0 (Reference)0 (Reference)
rs2228497-C/TCCC(1 copy)50.1%1.0 (0.9 -1.2)0.95−6 (−18 to 6)0.3364 (−79 to 206)0.38
rs1135473-C/TTCT(1 copy)37.1%1.1 (0.9 -1.3)0.281 (−11 to 13)0.88−32 (−173 to 109)0.66
rs12885336-C/TTCT(2 copies)5.1%1.4 (1.1 -1.9)0.02−24 (−47 to 0)0.05−238 (−507 to 31)0.08
CTC(1 copy)25.0%1.0 (0.9 -1.2)0.886 (−7 to 19)0.34−4 (−154 to 146)0.96
CTC(2 copies)2.2%0.9 (0.6 -1.5)0.79−5 (−42 to 31)0.7786 (−336 to 508)0.69
SSTR1 singletonMajor homozygote88.7%1.0 (Reference)0.740 (Reference)0.930 (Reference)0.37
rs2250885-A/GHeterozygote11.1%0.9 (0.8 -1.1)2 (−14 to 17)−78 (−262 to 106)
Minor homozygote0.2%1.9 (0.5 -7.0)−19 (−120 to 83)−203 (−1379 to 972)
SSTR2 block 1GGC(2 copies)44.5%1.0 (Reference)0 (Reference)0 (Reference)
rs7213907-G/AGGC(1 copy)43.7%1.0 (0.8 -1.2)0.910 (−13 to 13)0.9968 (−86 to 223)0.39
rs16977537-G/TATT(1 copy)29.9%0.9 (0.8 -1.1)0.39−15 (−28 to −1)0.03−125 (−281 to 31)0.12
rs1037257-C/TATT(2 copies)3.4%0.9 (0.6 -1.3)0.505 (−24 to 34)0.74−4 (−342 to 334)0.98
G\T(2 copies)1.1%1.2 (0.7 -2.2)0.5215 (−25 to 54)0.47285 (−179 to 749)0.23
SSTR2 singletonMajor homozygote93.5%1.0 (Reference)0.800 (Reference)0.670 (Reference)0.79
rs1037260-T/GHeterozygote6.5%0.9 (0.7 -1.2)4 (−16 to 25)33 (−208 to 274)
Minor homozygote0.0%− (−)− (−)− (−)
SSTR2 block 2AGG(2 copies)12.8%1.0 (Reference)0 (Reference)
rs2236750-A/GAGG(1 copy)44.7%1.0 (0.8 -1.1)0.66−14 (−26 to −2)0.02−37 (−172 to 98)0.59
rs728291-G/TATC(1 copy)44.0%1.0 (0.8 -1.1)0.50−2 (−14 to 9)0.7160 (−72 to 193)0.37
rs1466113-G/CATC(2 copies)13.2%0.9 (0.7 -1.1)0.32−6 (−26 to 14)0.53−44 (−277 to 190)0.71
GGG(1 copy)35.8%0.9 (0.8 -1.0)0.16−4 (−15 to 8)0.55−53 (−190 to 84)0.45
GGG(2 copies)5.8%0.8 (0.6 -1.1)0.21−25 (−51 to 1)0.06−155 (−459 to 150)0.32
AGC(1 copy)11.0%0.8 (0.6 -1.0)0.02−9 (−26 to 8)0.31−35 (−238 to 168)0.74
AGC(2 copies)0.1%0.7 (0.1 -4.6)0.74−103 (−244 to 38)0.15−1174 (−2820 to 472)0.16
Part B. Associations between genetic variation in SST and the SSTR genes and prostate cancer risk and circulating hormone levels
SSTR3 block1GGG(2 copies)12.6%1.0 (Reference)0 (Reference)0 (Reference)
rs6572-C/GGGG(1 copy)44.7%1.0 (0.9 -1.2)0.96−3 (−15 to 9)0.63−16 (−155 to 122)0.82
rs4820273-G/ACGA(1 copy)40.8%1.1 (1.0 -1.3)0.13−13 (−25 to −1)0.04−99 (−239 to 42)0.17
rs5756562-A/GCGA(2 copies)9.8%0.9 (0.7 -1.2)0.53−8 (−30 to 15)0.5010 (−251 to 272)0.94
GGA(1 copy)30.0%1.1 (0.9 -1.2)0.52−4 (−17 to 9)0.543 (−149 to 156)0.97
GGA(2 copies)4.0%1.3 (0.9 -1.8)0.20−14 (−45 to 17)0.3849 (−316 to 414)0.79
CAA(1 copy)23.1%1.1 (1.0 -1.3)0.184 (−10 to 17)0.60−5 (−161 to 152)0.95
CAA(2 copies)2.4%0.8 (0.5 -1.2)0.25−20 (−51 to 10)0.19−94 (−452 to 264)0.61
SSTR3 block2ACT(2 copies)13.6%1.0 (Reference)0 (Reference)0 (Reference)
rs9610669-A/CACT(1 copy)44.5%1.1 (1.0 -1.3)0.12−3 (−15 to 10)0.66−64 (−210 to 81)0.39
rs229569-C/TCTT(1 copy)32.4%1.0 (0.9 -1.1)0.81−8 (−19 to 4)0.21−69 (−208 to 69)0.33
rs229563-T/CCTT(2 copies)5.5%0.7 (0.5 -1.0)0.06−17 (−43 to 8)0.18101 (−197 to 399)0.51
ACC(1 copy)25.9%1.0 (0.9 -1.2)0.89−4 (−18 to 11)0.6149 (−119 to 216)0.57
ACC(2 copies)2.3%1.3 (0.9 -2.1)0.18−18 (−58 to 23)0.39−29 (−499 to 440)0.90
CCT(1 copy)25.4%1.0 (0.9 -1.2)0.71−12 (−27 to 4)0.14−22 (−197 to 154)0.81
CCT(2 copies)2.5%1.0 (0.6 -1.5)0.88−10 (−49 to 29)0.61−45 (−499 to 409)0.85
CCC(1 copy)20.8%1.0 (0.8 -1.2)0.87−14 (−30 to 2)0.08−40 (−225 to 145)0.67
CCC(2 copies)1.5%1.1 (0.6 -1.9)0.78−20 (−66 to 27)0.41−105 (−649 to 438)0.70
SSTR4TAG(2 copies)8.1%1.0 (Reference)0 (Reference)0 (Reference)
rs220979-T/ATAG(1 copy)42.8%1.0 (0.9 -1.2)0.76−4 (−18 to 9)0.5417 (−140 to 174)0.83
rs3746726-A/CTCG(1 copy)40.6%0.9 (0.8 -1.1)0.35−8 (−22 to 5)0.21−67 (−222 to 88)0.40
rs2007363-G/TTCG(2 copies)7.6%1.0 (0.7 -1.3)0.74−28 (−54 to −1)0.04−109 (−417 to 200)0.49
AAT(1 copy)33.2%1.0 (0.8 -1.2)0.810 (−13 to 14)0.9794 (−62 to 251)0.24
AAT(2 copies)5.1%0.8 (0.6 -1.1)0.173 (−25 to 31)0.86305 (−21 to 631)0.07
AAG(1 copy)27.7%1.0 (0.8 -1.2)0.74−4 (−19 to 10)0.5538 (−131 to 207)0.66
AAG(2 copies)3.1%0.8 (0.5 -1.2)0.2412 (−20 to 44)0.4668 (−305 to 440)0.72
SSTR5GTG(2 copies)9.5%1.0 (Reference)0 (Reference)0 (Reference)
rs213653-G/AGTG(1 copy)42.5%1.0 (0.9 -1.2)0.640 (−13 to 13)0.99−38 (−186 to 110)0.61
rs213654-T/CGCT(1 copy)42.7%0.9 (0.8 -1.1)0.222 (−11 to 16)0.7164 (−88 to 216)0.41
rs11644051-T/GGCT(2 copies)10.6%0.9 (0.7 -1.1)0.266 (−17 to 30)0.6092 (−183 to 367)0.51
ACT(1 copy)38.7%0.9 (0.8 -1.1)0.316 (−8 to 19)0.4132 (−122 to 186)0.68
ACT(2 copies)7.8%0.8 (0.6 - 1.1)0.1110 (−14 to 34)0.4239 (−244 to 322)0.79
GTT(1 copy)9.7%1.0 (0.8 -1.3)1.003 (−19 to 24)0.80−7 (−254 to 240)0.95
GTT(2 copies)0.7%0.5 (0.2 -1.3)0.1498 (26 -170)0.01951 (113-1789)0.03
ATT(1 copy)8.1%1.0 (0.7 -1.3)0.778 (−13 to 30)0.454 (−245 to 253)0.98
ATT(2 copies)0.2%0.6 (0.1 -2.9)0.5516 (−124 to 156)0.82−45 (−1,667 to 1577)0.96
SSTR5 -singletonMajor homozygote90.9%1.0 (Reference)0.200 (Reference)0.0020 (Reference)0.0003
rs4988483-C/AHeterozygote8.9%1.2 (0.96-1.5)−23 (−42 to −4)−333 (−553 to −112)
Minor homozygote0.3%0.6 (0.2 -2.1)−103 (−186 to −21)−1111 (−2065 to −156)
  • Abbreviation: OR, odds ratio.

  • * Odds ratios were assess by conditional logistic regression.

  • β-estimates refers to regression coefficients from linear regression model.